Alopecia future or investigational therapies
|
Alopecia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Alopecia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Alopecia future or investigational therapies |
|
Risk calculators and risk factors for Alopecia future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ogechukwu Hannah Nnabude
Overview
Stem cell research is currently the most promising method for the future in treatment of alopecia.
Future or Investigational Therapies
Hair Multiplication
Looking forward, the prospective treatment of hair multiplication/hair cloning, which extracts self-replenishing follicle stem cells, multiplies them many times over in the lab, and microinjects them into the scalp, has been shown to work in mice, and is currently under development, expected by some scientists to be available to the public in 2009–2015. Subsequent versions of the treatment are expected by some scientists to be able to cause these follicle stem cells to simply signal the surrounding hair follicles to rejuvenate. See Baldness treatments
In October 2006, UK biotechnology firm Intercytex announced they have successfully tested a method of removing hair follicles from the back of the neck, multiplying them and then reimplanting the cells into the scalp (Hair multiplication). The initial testing resulted in 70% of male patients regrowing hair. This treatment method is expected to be available to the public by 2009.[1]
In January 2007, Italian stem-cell researchers say they've come up with a new technique for curing baldness. Pierluigi Santi of a Genoa clinic said stem cells could be used to "multiply" hair roots. He said the clinic would be ready to perform its first hair transplants on priority patients - those who have lost their hair in fires or other accidents - within a few months. After that, he said, "we'll open our doors to paying customers". Santi's approach works by splitting roots and growing new follicles.